Introduction
Juvenile xanthogranuloma (JXG) is a benign histiocytosis characterized by histologic findings of lipid-laden histiocytes and giant cells [1] . It is the most common type of non-Langerhans histiocytosis that commonly affects the skin [1, 2] . The first ocular JXG that involved the iris was reported in 1948 at a meeting of the Ophthalmic Pathology Club in Washington, DC and subsequently published by Blank et al. one year later [3] . JXG of the eye has become an eyeopener in ophthalmology when 15 eyes were enucleated but 13 eyes were misdiagnosed with malignant intraocular tumor in a multicentre series of 20 cases of iris JXG [4] . We report here an interesting and rare case of eyelid JXG diagnosed in paediatric patient.
Case Presentation
A three-year-old Malay boy presented to the ophthalmology clinic with painless left upper eyelid mass for six months duration which gradually increased in size. Initially the small mass started at lateral 1/3 of the left upper eyelid. He denied any itchiness, redness, or discharge from the lesion. There was no history of similar presentation before. He was able to open his eye and the eyelid mass did not obstruct his vision. He denied any history of trauma, insect bite, or blurring of vision. The parents neither used traditional medication nor sought treatment prior to the presentation. In view of progressive growth of the mass which obstructed his lateral vision, he was brought to hospital to seek immediate treatment.
On examination, the vision for both eyes were 6/6 with no relative afferent pupillary defect. There was a left upper eyelid mass at the lateral 1/3 which was 1 x 1 cm, non-erythematous, nodular, and mobile from underlying structure (Figure 1) . The mass was non-tender and firm. The eyes were symmetrical, no proptosis and orthophoric in primary position. The conjunctiva was white and no mass noted. The cornea was clear and there was no hyphema. The iris was normal in colour and no iris heterochromia or iris nodule presented. Intraocular pressure was within normal range. The fundus revealed normal findings with no optic disc swelling or gliosis. He was initially treated with topical steroid. However, the mass did not resolve and he underwent excisional biopsy of the swelling of upper eyelid under general anaesthesia.
FIGURE 1: A pedunculated yellowish nodule at left upper eyelid.
The histopathology examination revealed a nodular lesion in the subepithelium composed of dense infiltration of lymphocytes, histiocytes, touton giant cells with some neutrophils and fibrous tissue seen amongst the inflammatory cells ( Figure 2 ). The findings were interpreted as juvenile xanthogranuloma (JXG). The patient was referred to paediatric unit to exclude systemic involvement of juvenile xanthogranuloma and it was confirmed that there was no systemic involvement present. At three months follow-up the swelling did not recur after the surgery and the surgical site healed with a faint scar. 
Discussion
Juvenile xanthogranuloma is a rare manifestation of ocular disease. The incidence of eye involvement in patients with cutaneous JXG was estimated to be 0.3% to 0.4%. In contrast, at least 41% of patients with ocular involvement had cutaneous lesions and they are always multiple in number [5] . Ocular involvement occurs more often during the first two years of life, but adult onset is also observed [5, 6] .
Iris is the most common ocular site for JXG. Iris JXG is usually asymptomatic but it can present with hyphema, glaucoma, erythema with signs of uveitis, or congenital/acquired heterochromia iridis [1] . The eyelid is the second common site for ocular JXG while the posterior segment JXG is very rare [7] . Orbital involvement is also unusual and appears to occur mainly during the perinatal period [1, 7, 8] .
Diagnosis of JXG is mainly by clinical histopathology. The tissue or sample is obtained by excision biopsy, paracentesis, iridectomy, or intravitreal sampling. Most of ocular JXG is treated either conservatively or with medical treatment rather than surgical intervention. In non-sight threatening condition, it can be treated with high-dose topical steroid, periocular steroid and systemic corticosteroid [2] . There has been reports of successfully treating limbal JXG using topical corticosteroids in a four-month-old male patient, and also using intralesional corticosteroid for congenital eyelid JXG in an 18-day-old infant [9, 10] .
In our patient, he was treated with topical steroid for two weeks. However, the swelling did not improve and thus excisional biopsy was planned as a diagnostic and therapeutic management for this patient. He was referred to paediatric team to rule out systemic involvement. It is important to realize the relationship of JXG with neurofibromatosis type I (NF1) and juvenile myelomonocytic leukemia (JMML). Zvulunov et al. studied this association and concluded that children with NF1 and JXG have a 20-to 30-fold higher risk for JMML than patients with NF1 without JXG [11] . On the other hand, children with newly diagnosed JXG, multiple skin lesions, and onset at two years or younger were found to be at greatest risk and should therefore be targeted for surveillance [5] . Table 1 shows published cases of ocular and orbital JXG. Glaucoma and hyphema are likely to develop when JXG involved the iris. Newell summarized that spontaneous hyphema can occur in ocular JXG which is self-limiting [12] . Early recognition is possible to prevent loss of the eye during acute stage of the disease. Based on the case reports, most of JXG that involved deep structures of the eye such as iris, retina or choroid are usually associated with systemic manifestation. Gharib et al. and Meyer et al. performed cutaneous biopsy as a guidance to diagnosed spontaneous hyphema [13, 14] . They successfully preserved the eye by treating the disease conservatively. 
Authors Year

Conclusions
Simple eyelid swelling due to JXG may associate with systemic involvement. The crucial parts in managing eyelid swelling are histopathological finding and identification of ocular and systemic association to prevent inevitable complications. In uncomplicated cases, conservative globe-sparing treatment has shown as the best option for tumor resolution with low incidence of recurrence.
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